Cargando…

The Burden of Progressive-Fibrosing Interstitial Lung Diseases

Despite conventional treatment, a proportion of interstitial lung disease (ILD) patients develop a progressive phenotype known as “fibrosing ILD with a progressive phenotype” (PF-ILD), characterized by worsening respiratory symptoms, decline in lung function, and early mortality. This review describ...

Descripción completa

Detalles Bibliográficos
Autores principales: Cottin, Vincent, Teague, Rhiannon, Nicholson, Lindsay, Langham, Sue, Baldwin, Mike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843847/
https://www.ncbi.nlm.nih.gov/pubmed/35178411
http://dx.doi.org/10.3389/fmed.2022.799912
_version_ 1784651353557041152
author Cottin, Vincent
Teague, Rhiannon
Nicholson, Lindsay
Langham, Sue
Baldwin, Mike
author_facet Cottin, Vincent
Teague, Rhiannon
Nicholson, Lindsay
Langham, Sue
Baldwin, Mike
author_sort Cottin, Vincent
collection PubMed
description Despite conventional treatment, a proportion of interstitial lung disease (ILD) patients develop a progressive phenotype known as “fibrosing ILD with a progressive phenotype” (PF-ILD), characterized by worsening respiratory symptoms, decline in lung function, and early mortality. This review describes the epidemiology, and the humanistic and economic burden of PF-ILDs other than idiopathic pulmonary fibrosis (non-IPF PF-ILD). A structured review of the literature was conducted, using predefined search strategies in Ovid MEDLINE and EMBASE, and supplemented with gray literature searches. The search identified 3,002 unique articles and an additional 3 sources were included from the gray literature; 21 publications were included. The estimated prevalence of non-IPF PF-ILD ranges from 6.9 to 70.3/100,000 persons and the estimated incidence from 2.1 to 32.6/100,000 person-years. Limited evidence demonstrates that PF-ILD has a significant impact on patients' quality of life, affecting their daily lives, psychological well-being, careers, and relationships. PF-ILD is also associated with significant economic burden, demonstrating higher healthcare resource use and direct costs compared with the non-progressive phenotype, and indirect costs, which include job losses. This review indicates that PF-ILD places a considerable humanistic burden on both patients and caregivers, and a substantial economic burden on healthcare systems, patients, and society.
format Online
Article
Text
id pubmed-8843847
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88438472022-02-16 The Burden of Progressive-Fibrosing Interstitial Lung Diseases Cottin, Vincent Teague, Rhiannon Nicholson, Lindsay Langham, Sue Baldwin, Mike Front Med (Lausanne) Medicine Despite conventional treatment, a proportion of interstitial lung disease (ILD) patients develop a progressive phenotype known as “fibrosing ILD with a progressive phenotype” (PF-ILD), characterized by worsening respiratory symptoms, decline in lung function, and early mortality. This review describes the epidemiology, and the humanistic and economic burden of PF-ILDs other than idiopathic pulmonary fibrosis (non-IPF PF-ILD). A structured review of the literature was conducted, using predefined search strategies in Ovid MEDLINE and EMBASE, and supplemented with gray literature searches. The search identified 3,002 unique articles and an additional 3 sources were included from the gray literature; 21 publications were included. The estimated prevalence of non-IPF PF-ILD ranges from 6.9 to 70.3/100,000 persons and the estimated incidence from 2.1 to 32.6/100,000 person-years. Limited evidence demonstrates that PF-ILD has a significant impact on patients' quality of life, affecting their daily lives, psychological well-being, careers, and relationships. PF-ILD is also associated with significant economic burden, demonstrating higher healthcare resource use and direct costs compared with the non-progressive phenotype, and indirect costs, which include job losses. This review indicates that PF-ILD places a considerable humanistic burden on both patients and caregivers, and a substantial economic burden on healthcare systems, patients, and society. Frontiers Media S.A. 2022-02-01 /pmc/articles/PMC8843847/ /pubmed/35178411 http://dx.doi.org/10.3389/fmed.2022.799912 Text en Copyright © 2022 Cottin, Teague, Nicholson, Langham and Baldwin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Cottin, Vincent
Teague, Rhiannon
Nicholson, Lindsay
Langham, Sue
Baldwin, Mike
The Burden of Progressive-Fibrosing Interstitial Lung Diseases
title The Burden of Progressive-Fibrosing Interstitial Lung Diseases
title_full The Burden of Progressive-Fibrosing Interstitial Lung Diseases
title_fullStr The Burden of Progressive-Fibrosing Interstitial Lung Diseases
title_full_unstemmed The Burden of Progressive-Fibrosing Interstitial Lung Diseases
title_short The Burden of Progressive-Fibrosing Interstitial Lung Diseases
title_sort burden of progressive-fibrosing interstitial lung diseases
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843847/
https://www.ncbi.nlm.nih.gov/pubmed/35178411
http://dx.doi.org/10.3389/fmed.2022.799912
work_keys_str_mv AT cottinvincent theburdenofprogressivefibrosinginterstitiallungdiseases
AT teaguerhiannon theburdenofprogressivefibrosinginterstitiallungdiseases
AT nicholsonlindsay theburdenofprogressivefibrosinginterstitiallungdiseases
AT langhamsue theburdenofprogressivefibrosinginterstitiallungdiseases
AT baldwinmike theburdenofprogressivefibrosinginterstitiallungdiseases
AT cottinvincent burdenofprogressivefibrosinginterstitiallungdiseases
AT teaguerhiannon burdenofprogressivefibrosinginterstitiallungdiseases
AT nicholsonlindsay burdenofprogressivefibrosinginterstitiallungdiseases
AT langhamsue burdenofprogressivefibrosinginterstitiallungdiseases
AT baldwinmike burdenofprogressivefibrosinginterstitiallungdiseases